What Exelixis Does
Exelixis is a profitable, commercial-stage oncology company built around cabozantinib, marketed as Cabometyx (tablets) and Cometriq (capsules). Cabozantinib is a multi-target tyrosine kinase inhibitor (TKI) approved for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), differentiated thyroid cancer, and neuroendocrine tumors. It is the market-leading TKI in RCC and represents approximately 91% of total revenue. FY2025 revenue reached roughly $2.1 billion, with 2026 guidance of $2.525–$2.625 billion. Q1 2026 revenue was $610.8M.
Exelixis IR· 2026
Cabometyx / Cometriq
Core franchise: 91% of revenue. Market-leading TKI across RCC, HCC, thyroid cancer, NET. 96% gross margin. Composition-of-matter patent expires August 2026, but use patents and formulation extend effective protection.
Zanzalintinib
Next-generation TKI. NDA accepted for metastatic colorectal cancer (combo with atezolizumab). PDUFA target: December 3, 2026. Seven pivotal studies ongoing. Management targets $5B annual revenue by 2033.
Collaborations
Merck collaboration on MRD+ colorectal cancer. Ipsen partnership for cabozantinib ex-US commercialization generating royalties. Takeda partnership for cabozantinib in Japan.
Investment Thesis in One Sentence
A high-margin oncology cash machine funding aggressive buybacks and a credible multi-tumor pipeline expansion, trading at 12.9x forward earnings with 41% ROE — priced like a value stock with a growth optionality on zanzalintinib approval.
Fundamentals
| Metric | Value | Signal |
|---|
| Revenue (FY25) | ~$2.1B | Profitable |
| Revenue Growth | 3.3% | Steady |
| 2026 Guidance | $2.525–$2.625B | +20% YoY mid |
| Q1 2026 Revenue | $610.8M | On track |
| Gross Margin | 96.4% | Best-in-class |
| Profit Margin (Net) | 35.1% | Strong |
| ROE | 41.0% | Excellent |
| Trailing P/E | 17.30x | Reasonable |
| Forward P/E | 12.90x | Cheap for quality |
| Debt / Equity | 8.8% | Minimal debt |
| Buyback Program | $750M | Active |
| Dividend Yield | 0% | No dividend |
| Analyst Target (avg) | $46.50–$47.70 | Below spot |
| Analyst Range | $40–$56 | 20 analysts, Buy |
Analyst Consensus Below Spot
The consensus average target ($46.50–$47.70) sits roughly 9% below the current $52.24 price. This is not bearish per se — targets lag after a +55% move from the 52W low ($33.76). The analyst range tops out at $56, and 20 analysts still rate it Buy. But it means the trade is framed as momentum-with-fundamental-support, not deep-discount mean reversion.
Earnings Track Record — 4 Consecutive Beats
Technical Analysis
| Price | $52.24 |
| RSI (14) | 58.89 |
| MACD | 0.910 |
| MACD Signal | 1.151 Bearish cross |
| EMA 20 | $51.59 |
| EMA 50 | $49.42 |
| EMA 200 | $44.75 |
| 50-day avg | $48.94 |
| 200-day avg | $43.70 |
| ATR (14) | $1.56 |
| 52W Range | $33.76 – $53.93 |
Above EMA200
Above EMA50
Stack 20>50>200
RSI healthy
MACD bear cross
Support / Resistance
| Level | Price | Basis |
|---|
| R3 | $56.00 | Analyst high target |
| R2 | $53.93 | 52W high / ATH |
| SPOT | $52.24 | Current price |
| S1 | $51.59 | EMA20 |
| S2 | $49.42 | EMA50 |
| S3 | $44.75 | EMA200 |
Technical Setup
Bullish structure intact but with a warning sign. The moving-average stack is perfectly ordered — EMA20 ($51.59) > EMA50 ($49.42) > EMA200 ($44.75) — with healthy separation. RSI at 58.89 is neutral-bullish, not overbought. Price sits only 1.3% above EMA20, so the move is not over-extended. However, the MACD has just made a bearish cross (0.910 below signal 1.151), suggesting short-term momentum is fading. The ATR of $1.56 (~3% of price) provides clean risk sizing. The setup is a continuation coil near the 52-week high: if price holds EMA20 ($51.59) and breaks above $53.93, the breakout confirms. A loss of EMA20 would target the EMA50 ($49.42).
Finviz· live
Capital Structure & Dilution
This is where EXEL separates itself from most of the biotech sector. There is no dilution risk — the share count is shrinking. SEC filings show no S-3 equity raise, no ATM program, no shelf registration, and no warrants outstanding.
SEC EDGAR· 2026
- Fresh $750M buyback authorization (May 2026) running through end-2027
- Shares outstanding declining — structural bid under the stock
- Funded entirely from operating cash flow, not debt
Capital return is structural — per-share economics improving mechanically
- No PIPE, no toxic convertibles, no warrants outstanding
- No aggressive bookrunners (Wainwright/Maxim/Dawson James)
- Debt/equity 8.8% — net cash balance sheet, self-funding
- SEC filings: only routine 8-K (earnings, officer changes), 10-K, 10-Q
Zero death-spiral exposure — a profitable large-cap funding itself from operations
Dilution Verdict: CLEAN
No S-3, no ATM, no warrants, no shelf registration. Insider transactions neutral (0 buys, 0 sells recent). Sharia-compliant with D/E 8.8%. The cleanest capital structure you will find in commercial-stage oncology.
Risk Analysis
Risk Profile: Moderate
A profitable, net-cash company with best-in-class margins and an active buyback. The primary risk is the cabozantinib patent cliff in August 2026, creating long-term franchise concentration exposure. Pipeline execution is binary but well-telegraphed.
Patent cliff Aug 2026
Revenue concentration
Pipeline binary
No dilution
Net cash
- Cabozantinib composition-of-matter patent expires August 2026
- Cabometyx/Cometriq represent 91% of total revenue
- Use patents and formulation patents extend effective protection beyond August 2026, but generic entry risk increases over time
- Zanzalintinib (PDUFA Dec 2026) is the designated franchise replacement, but not yet approved
The single biggest risk. Use/formulation patents provide a buffer, but this is existential long-term without zanzalintinib approval.
- STELLAR-303 phase III: second dual primary endpoint did NOT reach statistical significance
- NDA was accepted on OS data, but the partial miss adds regulatory uncertainty
- PDUFA December 3, 2026 — binary outcome on franchise replacement
- Seven pivotal studies ongoing; any further misses compress the growth premium
OS data was enough for NDA acceptance, but the partial endpoint miss adds uncertainty to the Dec PDUFA outcome
- 91% of revenue from a single molecule (cabozantinib)
- Any competitive displacement in RCC/HCC would be material
- Rival TKI + IO combos competing for label-expansion in key indications
Zanzalintinib is the hedge, but until approved, the P&L depends on one drug
- Consensus average: $46.50–$47.70 vs spot $52.24
- Implies the market is pricing in growth that consensus has not yet modeled
- Range $40–$56 — spot is in the upper quartile
- 20 analysts maintain Buy — targets may lag after +55% move
Price is ahead of consensus — upside requires continued re-rating, not mean reversion
- MACD (0.910) just crossed below signal (1.151)
- Short-term momentum fading, though both values remain positive
- RSI 58.89 is neutral — no divergence confirming a reversal
A minor signal — MACD bear crosses in an uptrend often resolve with consolidation, not reversal
- No ATM, no S-3 equity, no warrants, no toxic convertibles
- Debt/equity 8.8% — net cash, self-funding operations
- $750M buyback active — dilution is negative (shares shrinking)
- Not halted, not most shorted, no compliance issues, no FTD flags
Among the cleanest capital structures in commercial-stage biotech
Why the Risk Score is 5/10
The typical biotech fears — cash burn, dilution, going-concern doubt — do not apply. EXEL is profitable, generates real FCF, holds net cash, and is buying back stock. What raises the score to moderate is the patent cliff: cabozantinib's composition-of-matter patent expires August 2026. While use and formulation patents extend protection, 91% revenue concentration on a single molecule approaching patent expiry is a structural overhang. The zanzalintinib PDUFA (Dec 3, 2026) is the designated solution, but it carries its own binary risk after the STELLAR-303 partial endpoint miss.
Exelixis IR· 2026
Correlation & Diversification
| Pair | 60-Day Pearson | Interpretation |
|---|
| EXEL vs SPY | 0.218 | Very low — excellent diversifier |
| EXEL vs XLV | 0.298 | Low — idiosyncratic vs healthcare |
| EXEL vs XBI | 0.491 | Moderate — some biotech beta |
Diversification Value
EXEL's 0.218 correlation with SPY is unusually low for a $13B company. This makes it a strong portfolio diversifier — it moves largely on its own idiosyncratic catalysts (earnings, pipeline data, patent events) rather than broad market direction. Even within healthcare (XLV 0.298), the stock behaves independently. The moderate correlation with XBI (0.491) reflects some shared biotech sentiment, but is still well below the 0.7+ threshold where diversification benefit diminishes.
Trade Idea
Entry Zone
$51.50 – $52.50
EMA20 support zone
Stop Loss
$48.97
-6.3% · ATR × 2.5 below entry
Target 1
$53.93
+3.2% · 52W high retest
Target 2
$56.00
+7.2% · analyst high target
Risk / Reward
~1.3:1
TP1 basis · swing 10–15 days
Ramp-Up Trade — Starter Size
This is a ramp-up trade per startup protocol: sizing at 0.25% risk. The R/R of ~1.3:1 to TP1 ($53.93) is below the standard 1.5:1 minimum for full sizing, reflecting the ATH proximity and below-spot analyst consensus. Treat this as a pilot position to be scaled only on a confirmed breakout above $53.93 with volume.
Thesis
Buy the EMA20 pullback near the 52-week high with fundamental support. The cabozantinib franchise prints 96% gross margins at a 12.9x forward PE with 41% ROE — rare quality at this price. The $750M buyback provides a structural bid, and the zanzalintinib PDUFA (Dec 3, 2026) is a well-defined catalyst. Entry on the EMA20 support zone ($51.50–$52.50) with stop at $48.97 (2.5x ATR below mid-entry) gives a clean mechanical stop below the EMA50. TP1 at the 52-week high ($53.93); TP2 at the analyst high target ($56.00). Horizon: 10–15 days (swing). Low correlation with SPY (0.218) means this trades on its own catalysts, not market direction.
Catalysts
- 4 consecutive EPS beats: Q1'26 $0.87 vs $0.763 est (+14%), Q4'25 $0.94 vs $0.809 (+16.2%), Q3'25 $0.78 vs $0.671 (+16.2%), Q2'25 $0.75 vs $0.645 (+16.2%)
Yahoo Finance· live
- Zanzalintinib NDA accepted — PDUFA December 3, 2026 (metastatic CRC + atezolizumab)
Exelixis IR· 2026
- Merck collaboration on MRD+ colorectal cancer
- $750M buyback active — structural bid through end-2027
- 2026 revenue guidance $2.525–$2.625B represents ~20% growth at midpoint
Invalidation
- Daily close below $48.97 (stop loss — loss of EMA50 zone)
- Failed breakout above $53.93 followed by high-volume reversal under EMA20
- Negative regulatory signal on zanzalintinib NDA or CRL on Dec 3 PDUFA
- Any generic entry filing on cabozantinib ahead of use-patent expiration
Final Grade
| Conviction | 72% (Moderate-High) |
| Bias | Bullish |
| Profile | Momentum + Value |
| Risk Score | 5/10 (Moderate) |
| Sharia Compliance | Compliant (D/E 8.8%) |
Key Positives
- 96% gross margin, 41% ROE, 35% net margin — elite profitability
- 12.9x forward PE for a company beating estimates every quarter
- Zero dilution risk + active $750M buyback + SPY correlation 0.218
Key Risks
- Patent cliff August 2026 on 91%-of-revenue cabozantinib
- STELLAR-303 partial endpoint miss adds PDUFA uncertainty
- Consensus target below spot — requires re-rating not reversion
Mindset Tip
Buying near an all-time high with analyst targets below feels uncomfortable — that is the point. The best momentum stocks always look expensive on consensus because consensus lags. What matters: is the business quality real (yes — 96% margins, 4/4 beats, 41% ROE), is dilution risk real (no — shares shrinking), and is there a defined catalyst ahead (yes — PDUFA Dec 3). Size for the patent cliff risk: starter position, scale on confirmation. Do not chase above $53.93 without volume.
Disclaimer
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from Yahoo Finance, SEC EDGAR, Finviz, StockAnalysis.com, and Exelixis investor relations. Accuracy is not guaranteed. The cabozantinib patent cliff (August 2026) and zanzalintinib regulatory timeline (PDUFA December 3, 2026) are material events that may significantly impact the stock price.
The author holds no position in EXEL at the time of publication and has no business relationship with Exelixis, Inc.
MARKET WATCH